Results 1 to 10 of about 60,584 (224)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

BMC Cancer, 2012
Background Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Mian Afsar, Metodieva Anna, Badura Susanne, Khateb Mamduh, Ruimi Nili, Najajreh Yousef, Ottmann Oliver, Mahajna Jamal, Ruthardt Martin   +8 more
doaj   +3 more sources

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms [PDF]

Journal of Hematology & Oncology, 2016
Background Acquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM binding and kinase inhibition in patients with chronic myelogenous leukemia (CML).
Xiaoying Lan, Chong Zhao, Xin Chen, Peiquan Zhang, Dan Zang, Jinjie Wu, Jinghong Chen, Huidan Long, Li Yang, Hongbiao Huang, Bing Z. Carter, Xuejun Wang, Xianping Shi, Jinbao Liu   +13 more
doaj   +3 more sources

Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database [PDF]

SAGE Open Medicine
Objectives: Breakpoint Cluster Region (BCR)-Abelson tyrosine kinase (ABL) inhibitors are widely used in the treatment of blood cancers, particularly chronic myelogenous leukemia and are often combined with triazole antifungal agents to prevent fungal ...
Peitao Xie, Lishan Lu, Yixuan Tian, Rongrong Jia, Xuemei Tian, Pu Bai   +5 more
doaj   +2 more sources

Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells [PDF]

Acta Biochimica et Biophysica Sinica
The BCR-ABL fusion gene, formed by the fusion of the breakpoint cluster region protein (BCR) and the Abl Oncogene 1, Receptor Tyrosine Kinase (ABL) genes, encodes the BCR-ABL oncoprotein, which plays a crucial role in leukemogenesis.
Zeng Jianling, Liang Xinquan, Duan Lili, Tan Fenghua, Chen Liujie, Qu Jiayao, Li Jia, Li Kai, Luo Dixian, Hu Zheng   +9 more
doaj   +2 more sources

RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia [PDF]

eLife
Philadelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao, Beiying Dai, Xiaodong Li, Yixin Zhang, Chun Qiao, Yaru Qin, Zhao Li, Qingmei Li, Shuzhen Wang, Yong Yang, Yijun Chen   +10 more
doaj   +2 more sources

Sphagneticola Trilobata (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL

Plants, 2021
We will study the effects of the methanol extract of Sphagneticola trilobata (L.) Pruski (Asteraceae) (MeST) on the growth of leukemia cells that may contain the BCR/ABL gene. This study also clarifies the mechanism of this effect on these cells.
Hoang Thanh Chi, Nguyen Thi Lien Thuong, Bui Thi Kim Ly   +2 more
doaj   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Badura, Susanne, Falkenburg, J. H. Frederik, Liebermann, Marcus, Nijmeijer, Bart A., Ottmann, Oliver Gerhard, Pfeifer, Heike, Ruthardt, Martin, Tesanovic, Tamara, Wystub, Sylvia   +8 more
core   +11 more sources

Molecular Pathways: BCR-ABL [PDF]

Clinical Cancer Research, 2012
Abstract Aberrant tyrosine kinase activity plays a critical role in many hematologic disorders, including chronic myeloid leukemia characterized by the constitutive activity of BCR-ABL. ABL therefore represents a crucial target for new therapeutic strategies.
CILLONI, Daniela, SAGLIO, Giuseppe
openaire   +3 more sources

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis

Cell Death and Disease, 2021
Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR-ABL stability, we perform a screen against a panel of deubiquitinating enzymes ...
Shuoyi Jiang, Xiaoge Wang, Yuanming He, Hongbiao Huang, Biyin Cao, Zubin Zhang, Jinbao Liu, Qi Wang, Zhenqian Huang, Xinliang Mao   +9 more
doaj   +1 more source

BCR-ABL affects STAT5A and STAT5B differentially. [PDF]

PLoS ONE, 2014
Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors linking extracellular signals to target gene transcription. Hematopoietic cells express two highly conserved STAT5-isoforms (STAT5A/STAT5B), and STAT5
Michael Schaller-Schönitz, David Barzan, Andrew J K Williamson, John R Griffiths, Iris Dallmann, Karin Battmer, Arnold Ganser, Anthony D Whetton, Michaela Scherr, Matthias Eder   +9 more
doaj   +1 more source